keyword

Onabotulinumtoxina

keyword
https://read.qxmd.com/read/31895071/craniofacial-autonomic-dysfunction-in-migraine-implications-for-treatment-and-prognosis
#1
Melissa M Cortez, Leah Millsap, K C Brennan, Corey L Campbell
BACKGROUND: Craniofacial autonomic signs and symptoms (CASS) are relatively underrecognized in the evaluation of migraine headache. Yet, these features provide insight into diagnostic criterion, therapeutic approaches, and overarching disease burden. EVIDENCE ACQUISITION: This review aims to summarize relevant literature evaluating autonomic dysfunction, with focus on CASS, in migraine through targeted literature searches in PubMed. Full articles of original data published between 1974 and 2019 were identified using MeSH terms with no search limits...
December 30, 2019: Journal of Neuro-ophthalmology: the Official Journal of the North American Neuro-Ophthalmology Society
https://read.qxmd.com/read/31889312/the-headache-pipeline-excitement-and-uncertainty
#2
Alan M Rapoport, Peter McAllister
There are many new treatment options available for migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020. Small molecule CGRP receptor-blocking oral compounds, both for acute care and prevention, are also coming. Four neurostimulators are available, with others on the way. New acute treatments coming soon include the 5HT1F agonist lasmiditan, a zolmitriptan intradermal micro-needle patch, and a nasal mist sumatriptan with a permeability enhancer...
December 30, 2019: Headache
https://read.qxmd.com/read/31862326/onabotulinumtoxina-re-injection-for-refractory-detrusor-overactivity-using-3-4-injection-sites-results-of-a-pilot-study
#3
Esther Martínez-Cuenca, Miguel Angel Bonillo, Eduardo Morán, Enric Broseta, Salvador Arlandis
OBJECTIVE: To determine if repeated treatment with Onabot/A in less injections points, provides similar clinical efficacy, duration and adverse events compared with previous treatment. METHODS: Prospective data of neurogenic detrusor overactivity (NDO) and idiopathic detrusor overactivity (IDO) patients previously treated with Onabot/A according to standard technique. When patients requested for repeating procedure, they were treated with the same Onabot/A dose but with 3-4 injection sites...
December 17, 2019: Urology
https://read.qxmd.com/read/31842121/cost-effectiveness-of-long-term-targeted-onabotulinumtoxina-versus-peripheral-trigger-site-deactivation-surgery-for-the-treatment-of-refractory-migraine-headaches
#4
Anna R Schoenbrunner, Ibrahim Khansa, Jeffrey E Janis
BACKGROUND: Chronic migraines affect approximately 2% of the United States population and cost an estimated $17 billion per year. OnabotulinumtoxinA (BoNTA) is an FDA-approved prophylactic medication for chronic migraine headaches and is best injected in a targeted fashion into specific trigger sites. The purpose of this study is to determine the cost-effectiveness of long-term, targeted BoNTA versus peripheral trigger site deactivation surgery for the treatment of migraine headaches...
November 25, 2019: Plastic and Reconstructive Surgery
https://read.qxmd.com/read/31819582/real-world-safety-and-effectiveness-of-onabotulinumtoxina-treatment-of-crow-s-feet-lines-and-glabellar-lines-results-of-a-korean-postmarketing-surveillance-study
#5
Dong-Jin Yi, Seongjin Hwang, JunHyuk Son, Irina Yushmanova, Krystal Anson Spenta, Suzanne St Rose
Purpose: OnabotulinumtoxinA is approved in the Republic of Korea for the treatment of moderate-to-severe crow's feet lines (CFL) and glabellar lines (GL), separately or in combination. We assessed safety and effectiveness of onabotulinumtoxinA in real-world clinical practice. Patient and methods: This 4-year postmarketing surveillance study was conducted in the Republic of Korea in subjects with moderate-to-severe CFL. Subjects aged 18 to 75 years received onabotulinumtoxinA injections for CFL alone or in combination with GL...
2019: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/31791824/daxibotulinumtoxina-for-injection-has-a-prolonged-duration-of-response-in-the-treatment-of-glabellar-lines-pooled-data-from-two-multicenter-randomized-double-blind-placebo-controlled-phase-3-studies-sakura-1-and-sakura-2
#6
Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor Gallagher, Yan Liu, Gill Shears, Roman G Rubio
BACKGROUND: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development. Phase 2 data have shown it offers a more prolonged duration of response than onabotulinumtoxinA. OBJECTIVE: To further evaluate the efficacy, duration of response, and safety of 40 U DAXI compared with placebo in the treatment of glabellar lines. METHODS: Two identical, multicenter, randomized, double-blind, placebo-controlled, phase 3 studies were performed (NCT03014622 and NCT03014635 on www...
November 15, 2019: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/31782777/reply-onabotulinumtoxina-should-be-considered-in-medication-overuse-withdrawal-in-patients-with-chronic-migraine
#7
Judith A Pijpers, Michel D Ferrari, Gisela M Terwindt
No abstract text is available yet for this article.
November 29, 2019: Brain
https://read.qxmd.com/read/31782764/onabotulinumtoxina-should-be-considered-in-medication-overuse-withdrawal-in-patients-with-chronic-migraine
#8
Dirk Dressler
No abstract text is available yet for this article.
November 29, 2019: Brain
https://read.qxmd.com/read/31758548/wearing-off-effect-of-onabotulinumtoxina-near-the-end-of-treatment-cycle-for-chronic-migraine-a-4-year-clinical-experience
#9
Fawad A Khan, Alaa E Mohammed, Mugilan Poongkunran, Anilkumar Chimakurthy, Michael Pepper
INTRODUCTION: The injection interval for onabotulinumtoxinA (BoNTA) in the management of chronic migraine (CM) is 12 weeks (78-84 days). The aim of this study was to review patient-reported wearing off effect (WOE) of the therapeutic benefit of BoNTA near the end of the treatment cycle. We intended to describe the demographics of patients at baseline and compare groups of patients with multiple episodes of WOE. METHODS: We conducted a retrospective review of patients with CM who received uninterrupted BoNTA therapy from January 2014 to March 2018...
November 22, 2019: Headache
https://read.qxmd.com/read/31747825/exploratory-randomized-double-blind-placebo-controlled-trial-of-botulinum-therapy-on-grasp-release-after-stroke-prombis
#10
Amanda Claire Wallace, Penelope Talelli, Lucinda Crook, Duncan Austin, Rachel Farrell, Damon Hoad, Aidan G O'Keeffe, Jonathan F Marsden, Richard Fitzpatrick, Richard Greenwood, John C Rothwell, David J Werring
Background . OnabotulinumtoxinA injections improve upper-limb spasticity after stroke, but their effect on arm function remains uncertain. Objective . To determine whether a single treatment with onabotulinumtoxinA injections combined with upper-limb physiotherapy improves grasp release compared with physiotherapy alone after stroke. Methods . A total of 28 patients, at least 1 month poststroke, were randomized to receive either onabotulinumtoxinA or placebo injections to the affected upper limb followed by standardized upper-limb physiotherapy (10 sessions over 4 weeks)...
November 20, 2019: Neurorehabilitation and Neural Repair
https://read.qxmd.com/read/31738943/a-novel-approach-to-managing-post-retropubic-vaginal-sling-pain
#11
Sarah Martin, Esther Han, Kenneth M Peters
OBJECTIVE: To describe a novel technique of using peripheral nerve neuromodulation (PNNM) for the treatment of refractory, mesh-induced chronic pelvic pain. Chronic pelvic pain associated with mesh can be a debilitating complication and there is currently no consensus on treatment. PNNM has been shown to be successful in the treatment of post-traumatic neuralgias but has yet to be studied in mesh complications. MATERIALS AND METHODS: We present a case of a 50-year-old woman who had unrelenting pelvic pain after retropubic sling placement...
November 15, 2019: Urology
https://read.qxmd.com/read/31738113/cost-effectiveness-of-sacral-neuromodulation-versus-onabotulinumtoxina-for-refractory-urgency-urinary-incontinence-results-of-the-rosetta-randomized-trial
#12
Heidi S Harvie, Cindy L Amundsen, Simon J Neuwahl, Amanda A Honeycutt, Emily S Lukacz, Vivian W Sung, Rebecca G Rogers, David Ellington, Cecile A Ferrando, Christopher J Chermansky, Donna Mazloomdoost, Sonia Thomas
PURPOSE: Sacral neuromodulation and intradetrusor injection of onabotulinumtoxinA are therapies for refractory urgency-urinary incontinence. Sacral neuromodulation involves surgical implant of a device that can last 4-6 years, while onabotulinumtoxinA involves serial office injections. Objective was to assess cost-effectiveness of 2-stage implantation sacral neuromodulation versus 200 units onabotulinumtoxinA for the treatment of urgency-urinary incontinence. MATERIAL AND METHODS: Prospective economic evaluation concurrent with Refractory Overactive Bladder: Sacral NEuromodulation v...
November 18, 2019: Journal of Urology
https://read.qxmd.com/read/31735594/neurourological-management-after-failed-intradetrusor-onabotulinumtoxina-injections
#13
Apostolos Apostolidis, Anne P Cameron
There are more questions than answers in the explanation for failure of onabotulinumtoxinA injection. We need to define what criteria should be used to diagnose it, what local bladder, neurological, or possibly immune phenomena are responsible for it, and the best and safest way to proceed in these vulnerable patients. We propose a management algorithm that may be worth testing at each step in clinical trials.
November 14, 2019: European Urology Focus
https://read.qxmd.com/read/31707463/comparing-lanbotulinumtoxina-hengli-%C3%A2-with-onabotulinumtoxina-botox-%C3%A2-and-incobotulinumtoxina-xeomin-%C3%A2-in-the-mouse-hemidiaphragm-assay
#14
Lizhen Pan, Hans Bigalke, Bruno Kopp, Lingjing Jin, Dirk Dressler
LanbotulinumtoxinA (LAN) is manufactured and registered in China since 1994. Despite its widespread use in China and its increasing use in other Asian countries and in South America, it is not yet well known elsewhere. We wanted to compare its potency labelling using the mouse diaphragm assay (MDA), an isolated muscle model for botulinum toxin (BT) potency measurements, which is superior to clinical tests and which was recently refined as an alternative batch release assay for BT manufacturing. We also wanted to estimate LAN manufacturing quality by testing its inter-batch potency consistency...
December 2019: Journal of Neural Transmission
https://read.qxmd.com/read/31632735/treatment-of-at-level-spinal-cord-injury-pain-with-botulinum-toxin-a
#15
Audrey Chun, Isaiah Levy, Ajax Yang, Andrew Delgado, Chung-Ying Tsai, Eric Leung, Kristell Taylor, Stephanie Kolakowsky-Hayner, Vincent Huang, Miguel Escalon, Thomas N Bryce
Study design: Randomized, double-blinded, placebo-controlled, cross-over study. Objective: To explore whether botulinum toxin A (BoNTA) could be effective for treating at-level spinal cord injury (SCI) pain. Setting: Outpatient SCI clinic, New York, USA. Methods: Participants were randomized to receive subcutaneous injections of either placebo or BoNTA with follow-up (office visit, telephone, or e-mail) at 2, 4, 8, and 12 weeks to assess the magnitude of pain relief post injection...
2019: Spinal Cord Series and Cases
https://read.qxmd.com/read/31630241/treatment-of-blepharospasm-and-meige-s-syndrome-with-abo-and-onabotulinumtoxina-long-term-safety-and-efficacy-in-daily-clinical-practice
#16
Angela Jochim, Tobias Meindl, Christoph Huber, Tobias Mantel, Silke Zwirner, Florian Castrop, Bernhard Haslinger
INTRODUCTION: Thirty years after their approval, botulinum toxin injections still are the first-line therapy for blepharospasm. The aim of our study was to analyze long-term data concerning safety and efficacy in a large cohort over decades. METHODS: Treatment data of all patients with blepharospasm and Meige´s syndrome in our outpatient clinic having undergone at least three subsequent treatment sessions with current onabotulinumtoxinA or abobotulinumtoxin A were analyzed with respect to the course of dose, effect duration, side effects, patients´ satisfaction and occurrence/reasons for treatment discontinuation...
October 19, 2019: Journal of Neurology
https://read.qxmd.com/read/31625955/commentary-on-efficacy-patient-reported-outcomes-and-safety-for-millennial-subjects-treated-with-onabotulinumtoxina-for-moderate-to-severe-horizontal-forehead-lines
#17
Rohit Kakar
No abstract text is available yet for this article.
October 14, 2019: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/31625954/efficacy-patient-reported-outcomes-and-safety-for-millennial-subjects-treated-with-onabotulinumtoxina-for-moderate-to-severe-horizontal-forehead-lines
#18
Melanie D Palm, Julius Few, Tapan Patel, Marva Safa, Adrienne Drinkwater, Cheri Mao, Julie K Garcia
BACKGROUND: Millennials (aged 18-34 years) represent a growing segment of the facial aesthetic market. OBJECTIVE: To evaluate investigator-assessed efficacy, patient-reported outcomes (PROs), and safety for millennials versus subjects aged at least 35 years after onabotulinumtoxinA treatment of forehead lines (FHL) across 2 phase 3 studies. METHODS: Eligible subjects with moderate to severe FHL received onabotulinumtoxinA (FHL: 20 U; glabellar lines: 20 U, with/without 24 U in crow's feet line regions) or placebo...
October 14, 2019: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/31609787/onabotulinumtoxina-for-the-treatment-of-major-depressive-disorder-a-phase-2-randomized-double-blind-placebo-controlled-trial-in-adult-females
#19
Mitchell F Brin, Suresh Durgam, Arlene Lum, Lynn James, Jeen Liu, Michael E Thase, Armin Szegedi
This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS); secondary endpoints were Clinical Global Impressions-Severity and 17-item Hamilton Depression Rating Scale at week 6. A total of 255 adult females were treated. OnabotA 30 U approached significance compared to placebo on MADRS (mixed-effect model repeated measures least-squares mean difference: -3...
January 2020: International Clinical Psychopharmacology
https://read.qxmd.com/read/31604683/overactive-bladder-syndrome-treatments-and-their-effect-on-female-sexual-function-a-review
#20
REVIEW
Gali Levy, Lior Lowenstein
INTRODUCTION: Overactive bladder (OAB), the most common subtype of urinary incontinence, has a heavy price on quality of life, especially on sexual life. Unfortunately, most women rarely voice the worsening of sexual function, especially those who already suffer from OAB symptoms. It has been demonstrated that patients who suffer from OAB score lower on Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire and Female Sexual Function Index scores, meaning that their sexual function is debilitated...
October 9, 2019: Sexual Medicine
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"